Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Targeted Therapy
- Palliative Care
- Central Nervous System Tumors
- Gynecological Cancers
- Lung Cancers
- Gastrointestinal Cancer
- Haemato-Oncology
- Lymphoma
Abstract
Citation: Clin Oncol. 2021;6(1):1874.DOI: 10.25107/2474-1663.1874
NLRP3 Inflammasome Enhances Tumor Growth
Bernhard Ryffel
Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, Orleans, France
*Correspondance to: Bernhard Ryffel
PDF Full Text Mini Review | Open Access
Abstract:
Tumor cell derived danger signals known as DAMPs activate the NLRP3 inflammasome leading to IL-1β/IL-18 production conferring a pro-inflammatory environment. The inflammatory tumor environment enhances the tumor progression and metastasis. The NLRP3 inflammasome or IL-1/IL-18 represents promising therapeutic targets in cancer therapy, which is discussed in this
review. Alternative targets such TLRs and cGAS/STING dependent immune regulators need to be considered. The metabolome and microbiome of the host are additional factors contributing to a successful chemo- and immunotherapy.
Keywords:
Cite the Article:
Ryffel B. NLRP3 Inflammasome Enhances Tumor Growth. Clin Oncol. 2021;6:1874..
Search Our Journal
Journal Indexed In
